Active Targeting By Targeting Ligands

• Active Drug Targeting by Receptor-Specific Ligands
• Active Drug Targeting by Aptamers
• Active Drug Targeting by Peptides or Receptor-Ligands
• Active Drug Targeting by PEGylated Ligands

CD Bioparticles’ services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:

The challenges you might meet:

• Low cell-permeability of the drugs
• Low specificity of the targeting
• High dosage required for treatment
• High side-effect of the toxic chemotherapeutic agents
• Tedious searching and conjugation of receptor-targeting-moieties

Key Features

• Conjugatable receptor-targeting-moiety discovery

  • Antibodies, Aptamers, Affibody, Anticalins, and AdNectins discovery

  • Conjugatable cell-penetrating peptides

  • Conjugatable moieties discovery

• Liposome discovery

• Protein Toxins discovery

• Virus vector discovery

• Pro-drug discovery

  • Antibody-drug conjugation discovery

Key benefits:

• Wide coverage of the Antibodies, Aptamers, Affibody, Anticalins, and AdNectins meets your specific cell-membrane-transporter-targeting design
• Receptor-targeting-moiety modifications increase the uptake rate of the drugs
• Ready-to-use, reactive-end-group functionalized receptor-targeting-moieties simplifies your preparation procedures for labeling your drugs or your drug-loading cargos
• Drug-oriented, customized liposome production and formulation improves the delivery efficiency of the drugs, such as nucleic acids, peptides, or molecules
• GMP promises the quality of products
• Analytical platforms cover from drug fabrications to in-vitro and in-vivo tests

Application candidates:

• Large molecular, peptide or nucleic acid drugs with insufficient cell-permeability
• Toxic chemotherapeutic agents
• Nanoparticles with low targeting efficiency and low targeting specificity